Gardasil 9 HPV vaccine
Selected indexed studies
- Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial. (Lancet Infect Dis, 2023) [PMID:37475116]
- Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. (MMWR Morb Mortal Wkly Rep, 2015) [PMID:25811679]
- Update on Safety and Efficacy of HPV Vaccines: Focus on Gardasil. (Int J Mol Cell Med, 2021) [PMID:34703794]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial. (2023) pubmed
- Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. (2015) pubmed
- Update on Safety and Efficacy of HPV Vaccines: Focus on Gardasil. (2021) pubmed
- Non-sexual HPV transmission and role of vaccination for a better future (Review). (2020) pubmed
- Adverse events following 9-valent human papillomavirus vaccine (GARDASIL® 9) reported to the Vaccine Adverse Event Reporting System (VAERS), 2015-2024. (2025) pubmed
- Opportunities and challenges for human papillomavirus vaccination in China. (2024) pubmed
- Global Guidelines and Trends in HPV Vaccination for Cervical Cancer Prevention. (2025) pubmed
- Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9. (2019) pubmed
- Gardasil-9 Vaccine as a Possible Treatment Option for Human Papillomavirus Conjunctival Papilloma. (2023) pubmed
- Gardasil-9: A global survey of projected efficacy. (2016) pubmed